|Bid||105.00 x 400|
|Ask||105.79 x 100|
|Day's Range||109.88 - 111.54|
|52 Week Range||94.20 - 119.30|
|PE Ratio (TTM)||3.84|
|Expense Ratio (net)||0.47%|
The “Fast Money” traders share their final trades for the day including Advanced Micro Devices, Square, iShares Nasdaq Biotech ETF and Facebook.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) much like the entire stock market had a difficult two weeks. Fundamentally, TEVA stock is not cheap. TEVA stock is still close to an all-time pivot point, which is likely to hold in the long run.
With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.
Before looking at today’s trade idea, allow me to make it clear that in my mind, biotechnology stocks are best “traded” as a theme, i.e. This is largely because biotechnology stocks can be volatile due to FDA pipelines, among other potential news traps. To illustrate this point, on this first chart in the top half I plotted the IBB ETF and at the bottom half I divided CELG stock by the IBB ETF for a so-called ratio chart.
Under the agreement, the former acquired the exclusive license for the latter’s compound technology and related patents covering abaloparatide to develop, manufacture, and commercialize abaloparatide-SC. Radius entered into a licensing agreement with Eisai in June 2006, under which the former obtained the exclusive right and license to develop, manufacture, and commercialize elacestrant from the latter. Radius Health entered into a licensing and development agreement with Teijin Limited for abaloparatide-SC in July 2017.
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.
This article was originally published on ETF Trends.com. Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand ...
Biotech stocks face a challenging 2018. Large companies are feeling pressed to do growth-spurring deals while the rally in smaller firms has pushed up their prices. And then there are the management teams ...